6
Mar
2015
Esperion Jockeys For Place Between Statins and the Next Big Class of Heart Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Feb
2015
The Tularik Alumni: Where Are They Now?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Feb
2015
Who Is Poised To Go Public in 2015, and Who Isn’t?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Feb
2015
Global Blood Zeroes in on Sickle Cell, a Potentially Big, and Touchy, Opportunity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Feb
2015
Frazier, Versant Find an AFib Drug To Bet on at Laguna
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Feb
2015
How’s It Going at the Biotech Journalism Startup? Much Better Than Expected
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Feb
2015
Video: Alnylam’s John Maraganore and Canaan’s Julie Papanek at BIO CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Feb
2015
FAQs About the Timmerman Report
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Feb
2015
Former Dendreon CEO Lures Ex-Amgen Scientists to Immunotherapy Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Feb
2015
Seattle Genetics Commercial Boss Leaves for President Gig at Bristol-Myers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Feb
2015
Third Rock’s Obesity Hopeful, Ember Therapeutics, Closes Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2015
The Merck Exodus: Where Are the Talented People Going?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2015
Implications of the Biotech Boom on the Business and Science of R&D
[Editor’s Note: This post was written by Richard Pops] It is exciting to see the remarkable influx of capital into the biopharmaceutical industry over the past couple of years. More than just refilling depleted coffers, strategic investors are putting more money to work in excellent companies after a long period of relative scarcity. Capital can favorably change the risk profile... Read More